Skip to main content
SpringerLink
Log in

Das Endometriumkarzinom aus Sicht der Pathologie

Aktuelle Entwicklungen und Perspektiven

Endometrial carcinoma from the standpoint of pathology

Current developments and perspectives

  • Gynäkologie aktuell
  • Published:
Die Gynäkologie Aims and scope

Zusammenfassung

Die gut etablierten 4 molekularen Subtypen (POLEmut, MMRd, NSMP und P53abn) des Endometriumkarzinoms werden inzwischen mit konventionellen morphologischen Parametern in vereinheitlichten Risikoklassifikationen zusammengedacht. Die klinisch-therapeutische Relevanz besteht insbesondere in deeskalierenden Konzepten zur Vermeidung adjuvanter Therapien ohne Benefit für POLEmut-Karzinome. In fortgeschritteneren Stadien kommen hingegen die Testungen zur Checkpointinhibition und Anti-Her2-Therapie zum Zug. Ziel der Übersichtsarbeit ist es, Hintergründe und Vorschläge für eine praxistaugliche Implementierung an die Hand zu geben.

Abstract

The well-established four molecular subtypes (POLEmut, MMRd, NSMP, and P53abn) of endometrial carcinoma are today considered together with conventional morphological parameters in unified risk classifications. The clinical–therapeutic relevance lies especially in de-escalating concepts to avoid adjuvant therapies without benefit for POLEmut carcinomas. In more advanced stages, however, testing for checkpoint inhibition and anti-Her2 therapy might be considered. The aim of this review is to provide background information and suggestions for the practical implementation in clinical routine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Buda A, Papadia A, Zapardiel I et al (2016) From conventional radiotracer Tc-99(m) with blue dye to indocyanine green fluorescence: a comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a Laparoscopic approach. Ann Surg Oncol 23:2959–2965

    Article  PubMed  Google Scholar 

  2. Buza N (2021) HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med 145:687–691

    Article  CAS  PubMed  Google Scholar 

  3. Concin N, Matias-Guiu X, Vergote I et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12–39

    Article  PubMed  Google Scholar 

  4. Cree IA, White VA, Indave BI et al (2020) Revising the WHO classification: female genital tract tumours. Histopathology 76:151–156

    Article  PubMed  Google Scholar 

  5. De Boer SM, Powell ME, Mileshkin L et al (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 20:1273–1285

    Article  PubMed  PubMed Central  Google Scholar 

  6. De Boer SM, Wortman BG, Bosse T et al (2018) Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol 29:424–430

    Article  PubMed  Google Scholar 

  7. Ethier JL, Desautels DN, Amir E et al (2017) Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 147:158–166

    Article  CAS  PubMed  Google Scholar 

  8. Fader AN, Roque DM, Siegel E et al (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that Overexpress her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928–3935

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C et al (2021) Immune checkpoint inhibitors in endometrial cancer. Crit Rev Oncol Hematol 161:103306

    Article  PubMed  Google Scholar 

  10. Ignatov A, Lebius C, Ignatov T et al (2019) Lymph node micrometastases and outcome of endometrial cancer. Gynecol Oncol 154:475–479

    Article  PubMed  Google Scholar 

  11. Imboden S, Nastic D, Ghaderi M et al (2021) Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer. Gynecol Oncol 162:394–400

    Article  CAS  PubMed  Google Scholar 

  12. Jungen SH, Noti L, Christe L et al (2023) Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. Front Med 10:1110529

    Article  Google Scholar 

  13. Köbel M, Ronnett BM, Singh N et al (2019) Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int J Gynecol Pathol 38(Suppl 1):S123–S131

    Article  PubMed  Google Scholar 

  14. Kommoss FK, Karnezis AN, Kommoss F et al (2018) L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 119:480–486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. León-Castillo A, De Boer SM, Powell ME et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38:3388–3397

    Article  PubMed  PubMed Central  Google Scholar 

  16. León-Castillo A, Gilvazquez E, Nout R et al (2020) Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 250:312–322

    Article  PubMed  PubMed Central  Google Scholar 

  17. Levine DA, Network TCGaR (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73

    Article  PubMed  PubMed Central  Google Scholar 

  18. Mitric C, Bernardini MQ (2022) Endometrial cancer: transitioning from histology to genomics. Curr Oncol 29:741–757

    Article  PubMed  PubMed Central  Google Scholar 

  19. Oaknin A, León-Castillo A, Lorusso D (2020) Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives. Curr Opin Oncol 32:471–480

    Article  PubMed  Google Scholar 

  20. Okcu O, Şen B, Aşkan G et al (2023) Tumor budding is an independent prognostic factor to predict overall survival in endometrial endometrioid carcinoma: a retrospective study. Int J Surg Pathol 31:26–37

    Article  CAS  PubMed  Google Scholar 

  21. Rau TT, Bettschen E, Büchi C et al (2020) Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups. Mod Pathol 34(1):222. https://doi.org/10.1038/s41379-020-0626-9

    Article  CAS  PubMed  Google Scholar 

  22. Rau TT, Deppeler MV, Christe L et al (2022) Pathological processing of sentinel lymph nodes in endometrial carcinoma—routine aspects of grossing, ultra-staging, and surgico-pathological parameters in a series of 833 lymph nodes. Virchows Arch 481:421–432

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Talhouk A, Derocher H, Schmidt P et al (2019) Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res 25:2537–2548

    Article  CAS  PubMed  Google Scholar 

  24. Turashvili G, Colgan T, Mclachlin M et al (2022) Lynch syndrome screening of women with endometrial cancer: feasibility and outcomes in a community program. J Obstet Gynaecol Can 44:142–147

    Article  PubMed  Google Scholar 

  25. Van Den Heerik A, Horeweg N, Nout RA et al (2020) PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 30:2002–2007

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsklinikum und Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40255, Düsseldorf, Deutschland

    Christina Neppl &  Tilman T. Rau MHBA

  2. Institut für Pathologie Bern, Universität Bern, Bern, Schweiz

    Wiebke Solass & Lucine Christe

Authors
  1. Christina Neppl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wiebke Solass
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucine Christe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tilman T. Rau MHBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tilman T. Rau MHBA.

Ethics declarations

Interessenkonflikt

C. Neppl, W. Solass, L. Christe und T.T. Rau geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Tanja Fehm, Düsseldorf

Ludwig Kiesel, Münster

Rainer Kimmig, Essen

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neppl, C., Solass, W., Christe, L. et al. Das Endometriumkarzinom aus Sicht der Pathologie. Gynäkologie 56, 718–725 (2023). https://doi.org/10.1007/s00129-023-05143-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-023-05143-4

Schlüsselwörter

Keywords

Search

Navigation